Can long-acting shots keep schizophrenia symptoms away? new study investigates.
NCT ID NCT05473741
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study followed 51 people with schizophrenia who were already stable on long-acting injectable antipsychotics. Over 48 weeks, researchers checked every 12 weeks whether patients stayed well or had a relapse. The goal was to see how often symptoms return when medication adherence is assured, and to measure blood drug levels and side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre for Addiction and Mental Health
Toronto, Ontario, M6J 1H3, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new pill for schizophrenia pass its first human test?
- Can a new daily pill offer safer Long-Term control of schizophrenia?
- Can an Anti-Seizure drug quiet the brain and sharpen thinking in schizophrenia?
- Can a dissolving film tame agitation in schizophrenia?
- Can a phone app teach the brain to read social cues?
- Can a gentle brain current silence voices that medication Can't?